deletions, rearrangements, and gene amplification play important roles. One of the areas for future direction is to increase our ability to look at such end points. Initiated cells, however, are not cancer. They must undergo selection pressures and clonal expansion.
Cancer is a probabilistic disease, and it requires multiple mutational events. The probability of this happening is greatly enhanced through clonal expansion. If we look more closely at the events occurring in a cell or tissue after chemical exposure, it is clear that changes in the balance between metabolic activation and detoxication will occur at different places in the doseresponse curve (1) . In some cases metabolic activation will be saturated at high doses, leading to a supralinear dose response (Fig. 1, curve b) . Two well-known examples of this type of response are vinyl chloride and (4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone (NNK) . If only high-dose data were used in assessing risk to this type of response, risk would be underestimated. With other compounds, detoxication or DNA repair saturates at high doses ( Fig. 1 , curve c), in which case the risk associated with low doses would be overestimated. These generalizations are further affected by dose-related changes in cell proliferation. Whether the promutagenic lesion in DNA is the biologically effective dose of the genotoxic chemical under test or background DNA damage, it does not become a mutation unless cell proliferation occurs. Cell proliferation is also a dose-related phenomenon that will affect extrapolation of risk. If we are to advance the scientific underpinning of risk assessment, it will be important to avoid making statements that are all-encompassing and instead refer to data on specific compounds and specific relationships.
To better understand the role of cell proliferation in carcinogenesis, we need to consider the sources of mutation. Figure 2 is a modification of Loeb's scheme for the sources of human mutation (2) . Endogenous forms of DNA damage, free radicals, and polymerase errors are constantly present in all cells of the body. Regardless of whether these arise from endogenous or (4) that the extent of DNA protein cross-linking per ppm of formaldehyde is markedly decreased at concentrations below 6 ppm. Between 6 and 15 ppm, the dose to DNA is linear. Yet, this is the observable portion of the concentrationresponse curve for nasal cancer that is highly nonlinear, i.e., a 50-fold increase in cancer for a 2.5-fold increase in dose (Fig. 3) . Data from the new mechanisms-based bioassay reported at this meeting (5) replicates the initial bioassay, but has an additional important exposure group of 10 ppm. This provides new information on the concentration response for tumor induction and clearly demonstrates that the nonlinear response is a straight line from 6 to 15 ppm. The other three lines in Figure 3 present cell proliferation data at various time points in this study. What is clear from these data is that sustained increases in cell proliferation exhibit virtually the same concentration Table 2 demonstrates that d-limonene causes a 4-to 5-fold increase in cell proliferation in the epithelial cells of the proximal tubules in the male Fischer rat, a strain of rat that makes a2u-globulin, but that no increase in cell proliferation occurs in the NBR rat, which does not synthesize x2u-globulin (6) . As pointed out in a recent review by the Environmental Protection Agency (7), this male-rat-specific protein selectively binds certain chemicals or their metabolites, is freely filtered by the glomerulus, and is resorbed by the proximal tubule of the nephron, where it accumulates in cellular lysosomes. The Evidence of sustained increases in cell proliferation that are not associated with increases in neoplasia is, on the other hand, much less available, but must be seriously considered. The exact temporal association between increased cell proliferation and the induction of neoplasia is unknown at this time. It is clear from the data presented at this meeting on formaldehyde that a minimum of 3 months of sustained cell proliferation is needed to sharply increase the slope for nasal cancer incidence (5) . Likewise, it took 12 months for the nongenotoxic agent ethyl acrylate to induce forestomach tumors in rats (8) . Studies on a series of jet fuels that induce oc2-globulin nephropathy demonstrated that none of the fuels induced renal tumors when male rats were exposed for 90 days and then held for an additional 21 months, although several did induce kidney tumors when the exposures were for 12 months and the rats were held for an additional 12 months (7). Thus, it is likely that sustained increases in cell proliferation are required to induce carcinogenesis. If examples are found where sustained increases are present and no increase in neoplasia occurs, these will be excellent examples to pursue to better understand the critical mechanisms that are involved. Possible examples include the ua2u-nephropathy-inducing agent gabapentin (9) .
The third factor that could explain the lack of neoplasia in the presence of increased cell proliferation is selective cytotoxicity of initiated cells. Before this meeting, this mechanism seemed plausible, in that it represented the reverse of the Solt-Farber model for haptocarcinogenesis. However, initiated cells are far more susceptible to the cytotoxicity and apoptosis induced by some agents (10) . Likewise, terminal differentiation of proliferating cells would remove this population of initiated cells from progressing to cancer. Two additional mechanisms were presented at this meeting. Different responses to cell-cell communication could alter the carcinogenic response (11) , and maturation arrest could decrease the likelihood of these cells progressing to neoplasms (12) . Thus, a clear area for future research is to gain a better understanding of why some agents that enhance cell proliferation are carcinogenic, while others are not. The fact that not all agents that enhance cell proliferation are carcinogens does not negate enhanced cell proliferation as a causal mechanism for other agents. As is clear from the arguments presented above, the two situations are not mutually exclusive.
How then can we begin to factor new data into the risk assessment process? Data were presented at this meeting where increased incidences of cancer were only seen after animals were exposed to high doses of a nongenotoxic agent under conditions that result in increased cell proliferation, while humans are exposed to much lower doses. Likewise, the genotoxic agent formaldehyde induced a markedly increased incidence of nasal cancer under conditions that caused a similar increase in cell proliferation, even though the molecular dose was linear over that portion of the exposureresponse curve and humans are only exposed to concentrations not associated with increased cell proliferation. This meeting did not discuss nonlinearities in molecular dose; however, I mentioned vinyl chloride and formaldehyde as two examples. It (14) .
Perhaps the most important outcome of this meeting is the identification of future research needs to clarify the role of cell proliferation in carcinogenesis. It is clear that we need to expand our database in several directions. Future bioasssays should be designed in a manner to provide much more and better data on cell proliferation. Beginning with the subchronic studies, cell proliferation can be used to help establish the MTD. The data will be useful in understanding nonlinearities in dose response and will establish the correlations for increased cell proliferation and the induction or noninduction of neoplasia. These studies will provide test compounds for elucidating critical mechanisms in carcinogenesis. Understanding interactions between species-, sex-and tissue-specific susceptibility factors and cell proliferation in chemical carcinogenesis is another major need. Why are some tissues susceptible to cancer induction while others are not? Why is the rat bladder susceptible to calculi-induced bladder cancer and the mouse bladder not? Once a series of chemicals that have an adequate database on cell proliferation is available, we may be able to identify elements of the mutational spectra that are associated with background DNA damage and cell proliferation. If one can identify the cell proliferation equivalent of the aflatoxin-induced p53 mutation at codon 249, it may provide a marker for proliferation-induced neoplasia.
Let me end by addressing one of the organizing committee's opening questions: Should cell proliferation be used in risk assessment? This could also be restated as: Can science replace the emperor's new clothes? We have discussed the different degrees of rigor that are present in experiments and experimental data sets on cell proliferation. We should give equal thought to the degree of rigor that is present in the mathematical extrapolations of risk that are currently practiced. What is their basis? Have they ever been validated, and where they are taking us? Regulation is important to human health, but it also does not come without costs. These costs are many fold. If we do a poor job of communicating the causes of human cancer to society, we are not promoting the prevention and control of cancer. If society equates cigarette smoking with the "carcinogen of the week" because the risk assessments all look alike, we as scientists involved in cancer control have failed. We must begin to incorporate knowledge of mechanism into the risk assessment process to improve its accuracy. In this regard, cell proliferation is one piece of mechanistic data that should be evaluated for its impact on the dose response for carcinogenesis. It is clear that accurate risk assessments will be required to identify and prioritize those health issues of greatest importance.
